Multiplicity and the marginal benefits of bevacizumab in malignant solid tumours.
作者信息
Gay Nathan D, Tao Derrick, Prasad Vinay
机构信息
Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, U.S.A.
Division of Hematology and Medical Oncology, Knight Cancer Institute, Department of Preventive Medicine and Public Health, and Center for Health Care Ethics, Oregon Health and Science University, Portland, OR, U.S.A.
出版信息
Curr Oncol. 2019 Dec;26(6):e791-e792. doi: 10.3747/co.26.4845. Epub 2019 Dec 1.
Abstract
摘要
相似文献
1
Multiplicity and the marginal benefits of bevacizumab in malignant solid tumours.贝伐单抗在恶性实体瘤中的多重性及边际效益
Curr Oncol. 2019 Dec;26(6):e791-e792. doi: 10.3747/co.26.4845. Epub 2019 Dec 1.
2
The role of bevacizumab in solid tumours: A literature based meta-analysis of randomised trials.贝伐单抗在实体瘤中的作用：基于文献的随机试验荟萃分析。
Eur J Cancer. 2017 Apr;75:245-258. doi: 10.1016/j.ejca.2017.01.026. Epub 2017 Feb 24.
3
Efficacy and Safety Assessment of the Addition of Bevacizumab to Adjuvant Therapy Agents in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.在癌症患者辅助治疗药物中添加贝伐单抗的疗效和安全性评估：一项随机对照试验的系统评价和荟萃分析
PLoS One. 2015 Sep 2;10(9):e0136324. doi: 10.1371/journal.pone.0136324. eCollection 2015.
4
Introduction by the Guest Editors: Bevacizumab.客座编辑引言：贝伐单抗。
Cancer J. 2018 Jul/Aug;24(4):163-164. doi: 10.1097/PPO.0000000000000325.
5
[Bevacizumab Treatment for Malignant Glioma Based on Basic Research and Clinical Trial].基于基础研究与临床试验的贝伐单抗治疗恶性胶质瘤
Gan To Kagaku Ryoho. 2016 Jun;43(6):694-701.
6
FOLFIRI+bevacizumab induction chemotherapy followed by bevacizumab or observation in metastatic colorectal cancer, a phase III trial (PRODIGE 9--FFCD 0802).FOLFIRI联合贝伐单抗诱导化疗后序贯贝伐单抗或观察用于转移性结直肠癌：一项III期试验（PRODIGE 9-FFCD 0802）
Dig Liver Dis. 2015 Apr;47(4):271-2. doi: 10.1016/j.dld.2015.01.146. Epub 2015 Jan 20.
7
Systematic evaluation of bevacizumab in recurrent ovarian cancer treatment.贝伐单抗在复发性卵巢癌治疗中的系统评价。
J BUON. 2014 Oct-Dec;19(4):965-72.
8
Bevacizumab treatment for solid tumors: boon or bust?贝伐单抗治疗实体瘤：是福还是祸？
JAMA. 2011 Feb 2;305(5):506-8. doi: 10.1001/jama.2011.57.
9
The role of angiogenesis inhibitors re-challenge in colorectal cancer previously treated with bevacizumab: a meta-analysis of randomized controlled trials.血管生成抑制剂再次挑战在先前接受贝伐单抗治疗的结直肠癌中的作用：一项随机对照试验的荟萃分析。
Eur Rev Med Pharmacol Sci. 2017 Apr;21(7):1489-1494.
10
Bevacizumab for renal cell carcinoma, glioblastoma, and other solid tumors.贝伐单抗用于治疗肾细胞癌、胶质母细胞瘤及其他实体瘤。
Oncology (Williston Park). 2009 Oct;23(11 Suppl Nurse Ed):54-6.
引用本文的文献
1
An evaluation of selinexor's clinical trial portfolio: a cross-sectional study.塞利尼索临床试验组合评估：一项横断面研究。
Ther Adv Hematol. 2025 May 31;16:20406207251329174. doi: 10.1177/20406207251329174. eCollection 2025.
2
Clinical progress of anti-angiogenic targeted therapy and combination therapy for gastric cancer.胃癌抗血管生成靶向治疗及联合治疗的临床进展
Front Oncol. 2023 Jun 12;13:1148131. doi: 10.3389/fonc.2023.1148131. eCollection 2023.
本文引用的文献
1
Drug Development at the Portfolio Level Is Important for Policy, Care Decisions and Human Protections.组合层面的药物研发对于政策制定、医疗决策和人类保护至关重要。
JAMA. 2017 Sep 19;318(11):1003-1004. doi: 10.1001/jama.2017.11502.
2
The role of bevacizumab in solid tumours: A literature based meta-analysis of randomised trials.贝伐单抗在实体瘤中的作用：基于文献的随机试验荟萃分析。
Eur J Cancer. 2017 Apr;75:245-258. doi: 10.1016/j.ejca.2017.01.026. Epub 2017 Feb 24.
3
The impact of Bevacizumab (Avastin) on survival in metastatic solid tumors--a meta-analysis and systematic review.贝伐珠单抗（阿瓦斯汀）对转移性实体瘤生存的影响——一项荟萃分析和系统评价。
PLoS One. 2013;8(1):e51780. doi: 10.1371/journal.pone.0051780. Epub 2013 Jan 22.
4
Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis.贝伐珠单抗治疗相关癌症患者的死亡率：一项荟萃分析。
JAMA. 2011 Feb 2;305(5):487-94. doi: 10.1001/jama.2011.51.
5
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.贝伐单抗联合伊立替康、氟尿嘧啶和亚叶酸钙治疗转移性结直肠癌。
N Engl J Med. 2004 Jun 3;350(23):2335-42. doi: 10.1056/NEJMoa032691.
Zotero 插件